Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.

207940

Kedudukan dalam Saham #496
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Harga Saham
$1,028.49
Modal Pasaran
$47.88B
Perubahan (1 hari)
-3.67%
Perubahan (1 tahun)
-18.37%
Negara
KR
Perdagangan Samsung Biologics Co.,Ltd. (207940)

Kategori

Healthcare
Nisbah P/S bagi Samsung Biologics Co.,Ltd. (207940)
Nisbah P/S pada October 2026 TTM: 14.48
Menurut laporan kewangan dan harga saham terkini Samsung Biologics Co.,Ltd., nisbah P/S semasa (TTM) ialah 14.48. Pada akhir 2024, nisbah P/S syarikat ialah 19.31.
Sejarah nisbah P/S untuk Samsung Biologics Co.,Ltd. dari 2014 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
2026 (TTM) 14.48 -15.84%
2025 17.20 -10.95%
2024 19.31 27.07%
2023 15.20 -20.91%
2022 19.22 -50.09%
2021 38.51 -18.79%
2020 47.42 14.90%
2019 41.27 -11.58%
2018 46.67 -16.73%
2017 56.06 83.95%
2016 30.47 -74.24%
2015 118.31 15.20%
2014 102.70 0.00%
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
10.72 -25.93%
US
41.70 188.07%
US
4.19 -71.05%
AU
5.80 -59.96%
BE
10.44 -27.86%
NL